What investment strategy does Erganeo focus on?

Erganeo focuses on VC strategies in the private equity space.

How many portfolio companies does Erganeo have?

Erganeo has 33 active portfolio companies and 3 completed exits and 1 fund tracked on GP Intel.

Where is Erganeo headquartered?

Erganeo is headquartered in Paris, France.

What is Erganeo's assets under management?

Erganeo manages approximately €47M in assets under management.

What sectors does Erganeo invest in?

Erganeo invests across Healthcare, Software, Industrials, Energy, TMT.

What are Erganeo's recent exits?

Recent realized exits by Erganeo include: Carboneo (2024) to ETSEM; Brainvectis (2020) to Asklepios BioPharmaceutical; Open Agora (2020) to Jamespot.

Home/GPs/Erganeo

DetailCard

Erganeo

Paris, France·Founded 2012·

Venture Capital

·erganeo.fr

Erganeo is a SATT (Societe d'Acceleration du Transfert de Technologies) founded January 26 2012 in Paris (SIREN 539868224 SAS HQ 30 rue de Gramont 75002 Paris), funded by the French State through the Programme d'Investissements d'Avenir (PIA) and Secretariat General pour l'Investissement (SGPI). Erganeo covers 350+ Ile-de-France laboratories and around 20K researchers across Universite Paris Cite + Sorbonne Paris Nord + INALCO + EPST partners (CNRS INSERM INRIA Institut Pasteur AP-HP) via the ValoCite consortium. Around EUR 47.3M of public capital deployed since inception, creating 38 deeptech startups financing 236 projects and signing 140 licenses across biotech infotech and enertech. Confirmed exits Brainvectis 2020 to Asklepios BioPharmaceutical and Open Agora 2020 to Jamespot.

AUM

€47M

Funds

vintages 2012

Portfolio

Exits

Erganeo is a Paris venture capital firm with €47M AUM, 33 active companies and 3 exits.

SectorsHealthcare Software Industrials Energy TMT

Key takeaways

·Average hold across 3 realized deals: 4 years.
·Top sector focus: Biotech (25% of portfolio).

Sector breakdown

36 companies

Biotech

9 · 25%

Software

5 · 14%

Healthcare

5 · 14%

Industrials

3 · 8%

TMT

3 · 8%

MedTech

3 · 8%

HealthTech

2 · 6%

ClimateTech

1 · 3%

Key facts

HQParis, France

Founded2012

Websiteerganeo.fr

Recent exits

Erganeo sold Carboneo to ETSEM in 2024 after 4 years.

Erganeo sold Brainvectis to Asklepios BioPharmaceutical in 2020 after 5 years.

Erganeo sold Open Agora to Jamespot in 2020 after 3 years.

Coverage notes

1 fund tracked, 36 portfolio companies (33 active · 3 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Erganeo has raised, with its portfolio companies. Hand-checked from public filings.

1 fund

Fund

Strategy

Vintage

Size

Assets

Exits

Erganeo

VC2012€47M33 assets3 exits

2012 · 14yr

€47M

Unrealized

33 held

Company	Entry
AbilyCare HealthTech · France	2021
Argument Theory Software · France	2019
Augmented Endoscopy Healthcare · France	2019
Auressens Biotech · France	2021
Cobot One Industrials · France	2021
Dextrain Healthcare · France	2012
Ermium Therapeutics Biotech · France	2019
EVerZom Biotech · France	2019
Evora Biosciences Biotech · France	2020
Frema Biotech · France	2020
Greennovation France	2025
HephIA Software · France	2021
Icon Photonics TMT · France	2018
Imisca France	2020
Izonics Industrials · France	2022
Kastafiore HealthTech · France	2020
Lafame France	2025
Lytid TMT · France	2018
Methys Dx MedTech · France	2021
MilliDrop Healthcare · France	2015
Neurallys MedTech · France	2020
Octogone Medical France	2020
Orixha MedTech · France	2019
PegmaTiss BioTech Healthcare · France	2023
Persea Biotech · France	2022
Sequencia Software · France	2021
SideROS Biotech · France	2019
SkinDermic Healthcare · France	2018
Soléo-Ecosolutions AgTech · France	2016
Telomium Biotech · France	2020
uGetWin TMT · France	2021
Wastemy Industrials · France	2021
Wints Software · France	2021

Realized

3 exits

Company	Entry	Exit	Type	Buyer	MOIC
Brainvectis Biotech · France	2015	2020	Trade Sale	Asklepios BioPharmaceutical	–
Carboneo ClimateTech · France	2020	2024	Trade Sale	ETSEM	–
Open Agora Software · France	2017	2020	Trade Sale	Jamespot	–

About Erganeo

Erganeo is a venture capital platform based in Paris with capital deployed across 2 active fund vehicles and a founding year of 2012. The firm targets European and selectively global technology companies across healthcare, software, TMT and energy, with capital deployed across early-stage and Series A/B rounds alongside institutional limited partners.

Investment thesis

The platform deploys venture capital into healthcare, software, TMT and energy categories with a focus on technology-enabled businesses across France and selectively across Europe. Investment focus spans seed and growth stages with capital deployed across multiple rounds per portfolio company, supporting founder teams through international scaling and selective M&A activity. The fund structure enables longer holding periods than typical venture vehicles, supporting category-leadership outcomes in technology platforms with global ambitions.

Recent activity

Recent realised exits include Carboneo (energy, 2024), Methys Dx (healthcare, 2023), Argument Theory (diversified sectors, 2022) and HephIA (software, 2022). The platform tracks 2 fund vehicles, 22 active portfolio companies and 6 realised exits across the strategy's history.

Frequently asked questions

What investment strategy does Erganeo focus on?: Erganeo focuses on VC strategies in the private equity space.
How many portfolio companies does Erganeo have?: Erganeo has 33 active portfolio companies and 3 completed exits and 1 fund tracked on GP Intel.
Where is Erganeo headquartered?: Erganeo is headquartered in Paris, France.
What is Erganeo's assets under management?: Erganeo manages approximately €47M in assets under management.
When was Erganeo founded?: Erganeo was founded in 2012.
What sectors does Erganeo invest in?: Erganeo invests across Healthcare, Software, Industrials, Energy, TMT.
What are Erganeo's recent exits?: Recent realized exits by Erganeo include: Carboneo (2024) to ETSEM; Brainvectis (2020) to Asklepios BioPharmaceutical; Open Agora (2020) to Jamespot.